Simcha Therapeutics, a New Haven-based biotech focused on fighting cancer, announced Thursday it has raised $40 million in a Series B financing round. SR One Capital Management led the round, joined ...
When Avi Shemtov debuted pita-wrapped Arabic tacos at Simcha last summer, it was a way for the chef and his team to get creative with more casual fare than they were typically serving at the Sharon ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Simcha Therapeutics, a biotechnology company developing first-in-class biologic drugs to modulate powerful cytokine pathways, this week shared data at the American ...
NEW HAVEN, Conn. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments in cancer, today ...
Cytokines, such as interleukin-2, emerged decades ago as promising cancer treatments. After all, they were the first modern drugs to prove that the immune system could be targeted to treat cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results